Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 3, 2012, Pages 339-346

  Gallego, Gisselle ^a   Bridges, John F P ^a   Flynn, Terry ^b   Blauvelt, Barri M ^c,d   Niessen, Louis W ^a,e,f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d Innovara Inc   (United States)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Best worst scaling; Health technology assessment; Hepatocellular Carcinoma; Horizon scanning; Liver cancer; Preferences

Indexed keywords

BEST-WORST SCALING; HEALTH TECHNOLOGY ASSESSMENTS; HEPATOCELLULAR CARCINOMA; HORIZON SCANNING; LIVER CANCERS; PREFERENCES;

LOGISTICS; SCANNING; SURVEYS;

TECHNOLOGY;

ARTICLE; BEST WORST SCALING; BIOMEDICAL TECHNOLOGY ASSESSMENT; EVALUATION; HUMAN; LIVER CELL CARCINOMA; MEDICAL TECHNOLOGY; NORMAL HUMAN; PERCEPTION; PHYSICIAN ATTITUDE;

ASIA; BIOMEDICAL TECHNOLOGY; CARCINOMA, HEPATOCELLULAR; DATA COLLECTION; EUROPE; HEALTH PERSONNEL; HUMANS; LIVER NEOPLASMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 84866406165     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S026646231200027X     Document Type: Article

References (23)

1. Australia and New Zealand Horizon Scanning Network. Microwave ablation for hepatic tumours. Canberra: Department of Health and Ageing; 2008.
2. Bridges JF, Gallego G, Blauvelt BM. Controlling liver cancer internationally: A qualitative study of clinicians' perceptions of current public policy needs. Health Res Policy Syst. 2011;9:32.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepato-logy. 2005;42:1208-1236. (Pubitemid 43112690)
4. Douw K, Vondeling H. Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems. Int J Technol Assess Health Care. 2006;22:177-183.
5. Douw K, Vondeling H, Eskildsen D, Simpson S. Use of the Internet in scanning the horizon for new and emerging health technologies: A survey of agencies involved in horizon scanning. J Med Internet Res. 2003; 5:e6.
6. Douw K, Vondeling H, Oortwijn W. Priority setting for horizon scanning of new health technologies in Denmark: Views of health care stakeholders and health economists. Health Policy. 2006;76:334-345.
7. Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: The case of food safety. J Public Policy Marketing. 1992;11:12-25.
8. Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. Pharma-cogenomics. 2010;11:1679-1682.
9. Ibargoyen-Roteta N, Gutierrez-Ibarluzea I, Benguria-Arrate G, Galnares-Cordero L, Asua J. Differences in the identification process for new and emerging health technologies: Analysis of the EuroScan database. Int J Technol Assess Health Care. 2009;25:367-373.
10. Lord R, Suddle A, Ross PJ. Emerging strategies in the treatment of advanced hepatocellular carcinoma: The role of targeted therapies. Int J Clin Pract. 2011;65:182-188.
11. Louviere J, Flynn T. Using best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia. Patient. 2010;3;275-283.
12. Peng XQ, Wang F, Geng X, Zhang WM. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Rev Pro-teomics. 2009;6:551-561.
13. Robert G, Gabbay J, Stevens A. Which are the best information sources for identifying emerging health care technologies? An international Delphi survey. Int J Technol Assess Health Care. 1998;14:636-643. (Pubitemid 29029292)
14. Kessels R, Jones B, Goos P, Vandebroek M. The usefulness of Bayesian optimal designs for discrete choice experiments. Applied Stochastic Models in Business and Industry. 2011;27:193-196.
15. Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3:353-367.
16. Simpson S, Hiller J, Gutierrez-Ibarluzea I, et al. A toolkit for the identification and assessment of new and emerging health technologies. Birmingham: EuroScan; 2009:31.
17. Simpson S, Packer C, Carlsson P, et al. Early identification and assessment of new and emerging health technologies: Actions, progress, and the future direction of an international collaboration-EuroScan. Int J Technol Assess Health Care. 2008;24:518-525.
18. Stafinski T, Topfer LA, Zakariasen K, Menon D. The role of surgeons in identifying emerging technologies for health technology assessment. Can J Surg. 2010;53:86-92.
19. Street D, Street AP. Combinatorics of experimental design. Oxford: Clarendon Press; 1987.
20. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54:1273-1285.
21. Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opin In-vestig Drugs. 2010;19:265-274.
22. Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15(Suppl 4):34-41.
23. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist. 2006;11:790-800. (Pubitemid 44157567)